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Abstract 
Purpose of review: Glioblastoma represents one of the major challenges in 
neurooncology and approximately half of the patients are 60 years or older. We 
summarize the particular situation of elderly glioblastoma patients with a focus on 
therapeutic considerations. 
Recent findings: Favorable molecular markers such as mutations in the isocitrate 
dehydrogenase (IDH) 1 or 2 genes are virtually absent in glioblastomas in elderly 
patients. Treatment options are similar to the situation in young patients and comprise 
surgical resection, radiation therapy and alkylating chemotherapy. The performance 
status as well as comorbidities may have a stronger impact on the individual treatment 
decision than in young patients. The MGMT promotor methylation status allows for a 
stratification of treatment beyond the surgical intervention. In patients with MGMT 
promoter methylated tumors, monotherapy with temozolomide is superior to 
radiotherapy alone. Similarly, the benefit conferred by combined temozolomide-based 
chemoradiotherapy compared to radiotherapy alone is largely restricted to patients 
with MGMT promoter methylated tumors. At recurrence, no standard treatment has 
been established. 
Summary: The prognosis for elderly patients with glioblastoma remains poor. The 
MGMT promoter methylation status helps guiding treatment decisions and 
withholding inactive, but potentially harmful treatments. 
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Introduction  
Glioblastoma remains one of the major challenges in neurooncology. In contrast to 
the consistently increasing knowledge on the underlying biology of these tumors, only 
little progress has been made in the clinical setting. Glioblastoma is a tumor thought 
to be of neuroglial origin, typically characterized by astrocytic differentiation and 
additional histological features such as microvascular proliferation and necrosis (1). 
On the molecular level, no major differences have been found in glioblastomas from 
young and elderly patients except for the frequency of mutations in the isocitrate 
dehydrogenase (IDH) 1 and 2 genes. IDH mutations occur in approximately 5% of all 
glioblastomas and are associated with an improved prognosis (2). They are virtually 
absent in glioblastomas of elderly patients. Yet, the updated 2016 WHO classification 
indicates that IDH-mutantglioblastoma should be considered a distinct entity. 
Glioblastomas are diagnosed throughout all age groups with a median age at 
diagnosis of approximately 64 years (3). In patients aged 65 years or older, 
glioblastoma accounts for the vast majority of all gliomas and is much more frequent 
than WHO grade II or III gliomas. Hence, a significant proportion of patients is at an 
advanced age when the tumor is diagnosed. According to age-adjusted analyses, the 
incidence of glioblastoma is continuously increasing from young to old subjects with 
a highest incidence rate in patients aged 75 to 84 years (3). Is has remained unclear 
why these tumors become more frequent in the elderly. Host factors such as a less 
efficient function of the immune system may be a contributing factor but solid data 
which support this hypothesis are largely lacking. The dataset published by the 
Central Brain Tumor Registry of the United States (CBTRUS) indicates a 1-year 
survival rate for glioblastoma patients aged 65-74 years of 28.7% and for patients 
aged 75 years or older of only 12.1%. Five years after the diagnosis, only 2.4% of the 
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patients aged 65 to 74 and 1.1% of the patients aged 75 or older are alive (3).  
In most countries around the world, the life expectancy is continuously raising. As a 
result, it must be assumed that the number of elderly patients affected by glioblastoma 
will increase within the next years and decades. Hence, there is a considerable need of 
improved therapeutic strategies for elderly glioblastoma patients. In sharp contrast, 
only few randomized trials have been specifically designed and performed for this 
patient population. In many other trials where age was not a specific exclusion 
criterion, elderly patients are typically underrepresented because of frailty, 
comorbidities, the need of medication which is not compatible with study procedures 
or other reasons. Furthermore, there are frequently concerns regarding a potential 
quality of life impairment due to side effects of study drugs or other procedures which 
ultimately preclude enrolment in clinical trials. Thus, compared to younger patients, 
physicians and caregivers can only partially rely on robust data when it comes to 
treatment decisions. In the following, we summarize the current knowledge on 
treatment options for elderly glioblastoma patients.  
 
Biopsy or resection? 
Despite the characteristic features of glioblastoma that are found by computed 
tomography (CT) or magnetic resonance imaging (MRI), tissue is required for a 
definite diagnosis and increasingly also molecular marker assessment. Therefore, a 
biopsy or surgical resection is mandatory to allow for a histopathological 
characterization of the tumor tissue. The emergence of various molecular markers 
stresses the importance of a sufficient amount of tissue in order to be able to perform 
all desired analyses. 
It has long been discussed whether a gross total resection results in prolonged survival 
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in glioblastoma patients. A small prospective trial addressed this question in elderly 
patients with suspected glioblastoma. Patients older than 65 years were eligible and 
30 patients were randomized to undergo stereotactic biopsy or open craniotomy and 
resection. Only 19 patients were finally diagnosed with glioblastoma, 4 additional 
patients had an anaplastic glioma. These patients were subsequently treated with 
radiotherapy. The median overall survival (OS) was 171 days after craniotomy 
compared to 85 days after biopsy (p=0.035). Despite its obvious limitations such as 
the small sample size as well as the restriction of further treatment to radiotherapy, 
these data suggested that tumor resection is beneficial and prolongs the survival of 
elderly glioblastoma patients (4). These data are further supported by a number of 
retrospective analyses of larger patient cohorts. A case-control study compared 40 
glioblastoma patients aged 65 years or older to 40 patients matched for age, 
performance status, localization of the tumor and treatment beyond surgery. Tumor 
resection was associated with a longer median OS than biopsy (5.7 vs 4.0 months, 
p=0.02) (5). Another retrospective series of 142 elderly patients with newly diagnosed 
glioblastoma reported a median OS of 13.0 months following resection compared to 
only 4.0 months after biopsy (p<0.001) (6). Multivariate analyses of the randomized 
phase III studies, NOA-08 and Nordic (see below for details), also indicated that 
surgical resection is superior to biopsy alone (7, 8). Finally, there are data from 
prospective trials which took advantage of the fluorescent dye, 5-aminolevulinic acid 
(5-ALA), or intraoperative MRI in order to improve the extent of resection (9, 10). 
Both trials demonstrate that gross total resection is associated with prolonged 
progression-free survival (PFS). These trials enrolled mainly younger glioblastoma 
patients and the extrapolation to the elderly population must be done with caution. 
However, in light of all available data, it can be concluded that tumor resection 
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contributes to prolonged survival compared to biopsy also in elderly glioblastoma 
patients. 
 
The role of radiotherapy 
Because of the overall poor prognosis of elderly glioblastoma patients, it must be 
carefully assessed whether any kind of tumor-specific treatment beyond surgery is 
warranted. This is of particular importance in frail patients with comorbidities who 
may be unable to tolerate radiotherapy or pharmacotherapy or both and suffer from 
side effects with consequent impairment of their quality of life. Furthermore, there 
have been speculations that the benefit of any treatment beyond surgery regarding 
survival times would be minimal in the elderly. This question was addressed in a 
randomized trial in patients with newly diagnosed glioblastoma aged 70 or older. 
Following histological confirmation of the diagnosis, 85 patients were randomized to 
receive either best supportive care alone or postsurgical radiotherapy with 50 Gy in 
fractions of 1.8 Gy fractions in addition to supportive care. The combination of 
radiotherapy and supportive care resulted in a prolongation of progression-free 
survival (14.9 weeks vs. 5.4 weeks). The median overall survival, which was the 
primary endpoint, was 29.1 weeks for patients treated with radiotherapy plus 
supportive care but only 16.9 weeks in the cohort of patients receiving supportive care 
alone (HR 0.47; p=0.002). Regarding toxicity, radiotherapy was well tolerated and no 
severe adverse events related to radiotherapy were reported. Furthermore, there were 
no significant differences between the 2 cohorts in the evaluation of quality-of-life 
and cognitive function (11). It can therefore be concluded that radiotherapy is safe 
and active in elderly glioblastoma patients.  
One of the drawbacks of radiotherapy is the fact that the patients need to go the 
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hospital on a daily base for several weeks. Data from several trials support the use of 
hypofractionated radiotherapy in elderly patients. A trial comparing 40 Gy in 15 
fractions with standard radiotherapy consisting of 60 Gy in 30 fractions did not show 
a difference in overall survival which was 5.6 months for the shorter course and 5.1 
months for the standard schedule (12). Because of this study as well as data from 
other trials (e.g., Nordic, see below for details), hypofractionated radiotherapy has 
become a standard of care for elderly glioblastoma patients.  
In a trial performed by the International Atomic Energy Agency, hypofractionated 
radiotherapy with 40 Gy in 15 fractions was compared to a very short course 
radiotherapy consisting of 5 x 5 Gy. Patients with newly diagnosed glioblastoma aged 
65 years or older and patients aged 50 years or older with a Karnofsky performance 
score (KPS) between 50 and 70% were eligible. Between 2010 and 2013, 98 patients 
were enrolled. There was no difference regarding overall survival between the 2 
groups with a median OS of 7.9 months in the 5 x 5 Gy cohort and 6.4 months in the 
group of patients receiving 40 Gy in 15 fractions (p=0.988). The median PFS was 4.2 
months in both groups. No difference in quality of life was noticed at 4 and 8 weeks 
after treatment (13). However, because of the limited follow-up time of only 6.4 
months, a potential negative impact of the short one-week radiotherapy on the 
cognitive function of patients surviving for more than few months cannot be 
excluded. Thus, it remains doubtful that this radiation schedule will be embraced in 
countries where molecular testing and individualized treatment approaches are 
becoming increasingly available. 
 
Alkylating chemotherapy 
Since the introduction of temozolomide to the standard of care for younger 
 8 
 
glioblastoma patients, it has gained widespread use (14). It is available as an oral 
formulation and overall well tolerated which makes it convenient for patients as it 
does not require daily treatment in a hospital. However, its use in elderly glioblastoma 
patients was not established for many years because of lacking data from prospective 
studies. Monotherapy with temozolomide was assessed in a non-randomized phase II 
trial in glioblastoma patients aged 70 or older and a postoperative KPS of less than 
70%. The drug was administered at a dose of 150-200 mg/m2 for 5 days every 28 
days. Temozolomide was overall well tolerated with grade 3 to 4 neutropenia and 
thrombocytopenia in 13% and 14% of patients, respectively. Median PFS was 16 
weeks and median OS was 25 weeks. In 23 out of 70 enrolled patients, KPS 
improvement of at least 10 points was noticed. Furthermore, an improvement of 
quality of life and cognitive function was reported. As expected, a methylated O6-
methylguanine-DNA methyltransferase (MGMT) promoter in the tumor tissue was 
associated with longer PFS and OS (15). Although a control arm of patients who 
received only best supportive care was lacking, the authors concluded that 
temozolomide is active as single agent treatment. 
 
Trials comparing radiotherapy and chemotherapy 
The therapeutic activity of monotherapy with temozolomide compared to 
radiotherapy in elderly patients with newly diagnosed glioblastoma was addressed in 
2 randomized phase III studies. The Nordic trial randomly assigned 291 elderly 
patients aged 60 years or older with newly diagnosed glioblastoma to one of three 
different treatment regimens: i) monotherapy with temozolomide given at 5 out of 28 
days with 150-200 mg/m2, ii) standard radiotherapy with 60 Gy in 30 fractions or iii) 
hypofractionated radiotherapy of 10 x 3.4 = 34 Gy (8). In the intention to treat (ITT) 
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population, there was no difference in the outcome of patients treated with 
temozolomide or hypofractionated radiotherapy (HR 0.82). Somewhat surprisingly, 
patients who were treated with hypofractionated radiotherapy had a significantly 
longer median OS than patients who received standard radiotherapy within the ITT 
population in the subgroup of patients aged 70 years or older (7.0 vs 5.2 months, 
p=0.02). This might be explained by the fact that more patients in the standard 
radiotherapy cohort did not complete the radiotherapy schedule. These data further 
support the use of hypofractionated radiotherapy in elderly glioblastoma patients as 
indicated above.  
A similar study, the randomized phase III NOA-08 trial, assessed monotherapy with 
temozolomide administered in a dose-intensified regimen of 100 mg/m2 given on days 
1–7 every other week and compared this regimen to standard radiotherapy consisting 
of 60 Gy given in 30 fractions. Patients aged 65 years or older with newly diagnosed 
glioblastoma (89%) or anaplastic astrocytoma (11%) were enrolled. Regarding overall 
survival, temozolomide was non-inferior to radiotherapy (HR 1.09). The overall 
survival rate after 12 months was 34.4% in the cohort of patients treated with 
temozolomide and 37.4% in the radiotherapy group (7). Most importantly, the results 
of the Nordic and the NOA-08 trials suggest that the survival benefit conferred by 
temozolomide is largely restricted to patients with tumors harboring a methylated 
MGMT promoter. MGMT promoter methylation was predictive for benefit from 
temozolomide treatment whereas patients with MGMT promoter unmethylated 
tumors displayed a trend for inferior survival. In contrast, the MGMT promoter 
methylation status was not associated with differential therapeutic activity of 
radiotherapy. 
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Combined radiochemotherapy 
Subgroup analyses of the pivotal EORTC/NCIC trial that resulted in temozolomide-
based radiochemotherapy as the new standard of care for younger patients with newly 
diagnosed glioblastoma had indicated that the benefit conferred by the addition of 
temozolomide is vanishing with increasing age (14, 16). Particularly in patients aged 
65 or older, no increase in survival was observed. Of note, the trial was not powered 
for these subgroup analyses. Still, because of these data as well as the results of the 
NOA-08 and Nordic trials, most European centers used either radiotherapy alone or 
monotherapy with temozolomide in elderly glioblastoma patients according to the 
MGMT promoter methylation status. The addition of temozolomide to radiotherapy 
compared to radiotherapy alone in patients with newly diagnosed glioblastoma aged 
65 years or older was finally examined in the NCIC/EORTC phase III trial 
(NCT00482677). Radiotherapy was administered with 40 Gy in 15 fractions. In the 
experimental group, concomitant temozolomide (75 mg/m2 daily during radiotherapy) 
and maintenance treatment with temozolomide (150-200 mg/m2 on days 1-5 of a 28 
days cycle) for up to 12 cycles or until progression was added. A total of 562 patients 
were enrolled. As expected, the addition of temozolomide resulted in hematological 
toxicity that was manageable in most patients. The median OS in patients treated with 
radiotherapy alone was 7.6 months versus 9.3 months in patients treated with 
radiochemotherapy (HR=0.67; p<0.0001). The addition of temozolomide also 
resulted in a prolonged PFS of 5.3 months versus 3.9 months (HR=0.50; p<0.001). 
Patients with MGMT promoter-methylated tumors had a strong benefit from 
temozolomide chemotherapy with a median OS of 13.5 months compared to only 7.7 
months in the radiotherapy group (HR=0.53; p<0.0001). In patients with MGMT 
unmethylated tumors, there was a non-significant trend favoring the 
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radiochemotherapy group (median OS 10.0 months vs. 7.9 months; HR=0.75; 
p=0.055) (17). Of note, the results for all subgroups analyses stratified for the MGMT 
promoter methylation status are better than for the overall cohort suggesting that 
patients with a poor outcome, most likely patients who had a biopsy only, are 
underrepresented in these analyses. The publication of the full dataset needs to be 
awaited to allow for final conclusions.  
Based on the results of this study as well as the Nordic and NOA-08 trials, 
temozolomide-based radiochemotherapy might be considered as a standard of care in 
elderly glioblastoma patients with a good KPS, allowing for combined modality 
treatment, and tumors harboring a methylated MGMT promoter. Patients with 
MGMT promoter unmethylated tumors may still be candidates for radiotherapy alone 
(Figure 1). Monotherapy with temozolomide might be an option if the MGMT 
promoter is methylated and combined radiochemotherapy is considered inappropriate 
because of a reduced KPS or an extensive field of radiotherapy or other reasons. 
 
Beyond radiotherapy and alkylating chemotherapy 
There has been a long-lasting interest in finding additional treatment options for 
glioblastoma patients. The monoclonal antibody bevacizumab targets vascular 
endothelial growth factor (VEGF). First reports on its administration to glioblastoma 
patients were followed by a period of optimism regarding its potential implementation 
into the standard of care. Initially, the situation seemed to be particular promising for 
elderly glioblastoma patients. According to a retrospective single center series, 
treatment with bevacizumab was supposed to have a more pronounced effect in 
recurrent glioblastoma patients with advanced age (18). It was assumed that this may 
reflect differences in the biology of tumors in young compared to older patients. 
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Similarly, data from early prospective studies pointed to a benefit from bevacizumab 
treatment in frail or elderly patients (19, 20). However, this optimistic view was not 
endorsed by subgroup analyses from 2 large randomized phase III trials assessing the 
addition of bevacizumab to temozolomide-based radiochemotherapy in patients with 
newly diagnosed glioblastoma. Both trials, AVAglio and RTOG 0825, demonstrated 
that bevacizumab prolongs progression-free survival but has no impact on overall 
survival (21, 22). Of note, none of these trials was designed to specifically clarify the 
role for bevacizumab in the context of elderly glioblastoma patients. However, there 
was a significant proportion of patients aged 65 years or older in both studies. There 
was a trend for more benefit from beacizumab in elderly patients with MGMT 
promoter unmethylated tumors in the AVAglio trial. Yet, frail patients were 
underrepresented as KPS was an inclusion criterion. A randomized phase II study 
assigned elderly glioblastoma patients to hypfractionated radiotherapy alone or 
radiotherapy plus bevacizumab (ARTE, NCT01443676). The results of this trial will 
define whether bevacizumab might be further investigated in the context of elderly 
glioblastoma patients, particularly in those with MGMT promoter-unmethylated 
tumors. The elderly patient population may be considered particularly suitable to 
explore novel agents which should be tested initially in combination with 
radiotherapy or temozolomide alone, but not combined modality treatment. Such an 
approach is pursued by the EORTC Brain Tumor Group for a the novel multikinase 
inhibitor TG02 (23). 
 
Treatment at recurrence 
No standard of care has been established so far for elderly glioblastoma patients when 
the tumor recurs. Obviously, the situation is not much different in younger patients 
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where positive data from randomized trials in patients with recurrent glioblastoma are 
largely lacking. Basically, re-resection can be offered but only a minority of elderly 
patients are considered appropriate candidates for such an approach due to 
comorbidities or tumor dimensions which preclude a gross total resection. Depending 
on the performance status, prior treatment and time between last treatment and tumor 
recurrence, several options may be available. Radiotherapy should be used when the 
tumor recurs in elderly patients with tumors harboring a methylated MGMT promoter 
who had first-line therapy with temozolomide monotherapy (7, 8). If not used as first-
line treatment, chemotherapy with temozolomide or lomustine/CCNU can be 
considered. The use of alkylating chemotherapy, however, is of limited benefit in 
patients with MGMT promoter-unmethylated tumors. Re-exposure to temozolomide 
is a salvage treatment that might be considered in patients with MGMT promoter 
methylated tumors following an interval with stable disease after initial treatment with 
the drug (24).  
Novel compounds that have been explored in phase III trials in patients with recurrent 
glioblastoma comprise enzastaurine and cediranib. Both drugs did not confer a 
survival benefit compared to lomustine. Furthermore, only a minority of patients were 
frail or elderly. Bevacizumab has been approved in the US and some other countries 
in patients with recurrent glioblastoma. However, the combination of bevacizumab 
and lomustine did not prolong overall survival in patients with recurrent glioblastoma 
compared to lomustine alone. Subgroup analyses did not point to an activity of 
bevacizumab in elderly patients (25). In summary, the treatment for elderly patients 
with progressive or recurrent glioblastoma has not been standardized and randomized 
trials would be required to make significant progress.  
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Current drug development and outlook 
Further research efforts in glioblastoma patients that are currently being investigated 
involve mainly immunotherapeutic approaches (26). Beyond vaccines which have 
been explored in neurooncology for several decades, there is a major interest in the 
use of checkpoint inhibitors. This class of new drugs comprises antibodies which 
target immune cell receptors or the corresponding ligands in order to strengthen and 
prolong anti-tumor immune responses (27). Immune checkpoint inhibitors such as the 
programmed cell death (PD)-1-blocking antibodies nivolumab or pembrolizumab 
have been approved for various cancers and are currently being tested in clinical trials 
in patients with newly diagnosed as well as recurrent glioblastoma (28). Although 
many of the ongoing trial do not specifically exclude elderly patients, it remains even 
more doubtful than in younger patients whether immunotherapy will result in clinical 
benefit in the elderly. First, the immune system is supposed to be less active in the 
elderly and whether a therapeutic intervention results in a clinically meaningful anti-
tumor immune responses is unclear. Second, some immunotherapeutics can exert 
severe side effects, particularly when different checkpoint inhibitors are used in 
combination. It must be assumed that elderly patients will again be underrepresented 
in the ongoing phase II and III trials which explore the activity of vaccines and 
checkpoint inhibitors (29). Similar to the conventional treatment options, well-
designed trials particularly addressing the needs of older patients will be required to 
define the role of immunotherapy in the treatment of these patients.  
 
Conclusions 
• Glioblastoma is more frequently diagnosed in the elderly for unknown 
reasons. 
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• Treatment options after biopsy or resection include radiotherapy and 
chemotherapy with the alkylating agent, temozolomide. 
• The Nordic and NOA-08 trials demonstrate a predictive role of MGMT 
promoter methylation for benefit from temozolomide treatment alone as 
opposed to radiotherapy alone. Hence, assessment of the MGMT promoter 
methylation status is warranted in elderly patients in order to define the ideal 
therapeutic strategy. 
• Temozolomide is typically used in the 5/28 days regimen because of the 
similar results from the Nordic and NOA-08 trials. Furthermore, data from the 
RTOG 0525 trial which mainly enrolled younger glioblastoma patients, do not 
point to a superiority of a dose-intensified temozolomide regimen (30). 
• Bevacizumab does probably not prolong the survival of elderly glioblastoma 
patients.  
• No standard of care has been established for elderly patients with recurrent 
glioblastoma. 
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Figure legend 
 
Figure 1. Treatment algorithm for elderly patients with newly diagnosed 
glioblastoma. MGMT, O6-methylguanine-DNA methyltransferase; RT, radiotherapy; 
TMZ, temozolomide. 
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